JP2015511599A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015511599A5 JP2015511599A5 JP2014561543A JP2014561543A JP2015511599A5 JP 2015511599 A5 JP2015511599 A5 JP 2015511599A5 JP 2014561543 A JP2014561543 A JP 2014561543A JP 2014561543 A JP2014561543 A JP 2014561543A JP 2015511599 A5 JP2015511599 A5 JP 2015511599A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- seq
- polypeptide
- soluble
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 50
- 229920001184 polypeptide Polymers 0.000 claims 26
- 102000004196 processed proteins & peptides Human genes 0.000 claims 26
- 108090000765 processed proteins & peptides Proteins 0.000 claims 26
- 101150096839 Fcmr gene Proteins 0.000 claims 23
- 102000039446 nucleic acids Human genes 0.000 claims 11
- 108020004707 nucleic acids Proteins 0.000 claims 11
- 150000007523 nucleic acids Chemical class 0.000 claims 11
- 239000000178 monomer Substances 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 230000000694 effects Effects 0.000 claims 5
- 108020001507 fusion proteins Proteins 0.000 claims 5
- 102000037865 fusion proteins Human genes 0.000 claims 5
- 238000000034 method Methods 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 230000037430 deletion Effects 0.000 claims 3
- 238000012217 deletion Methods 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 101000878510 Homo sapiens Fas apoptotic inhibitory molecule 3 Proteins 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 102000051981 human FCMR Human genes 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000003352 Hyper-IgM Immunodeficiency Syndrome Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029379 Neutrophilia Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 206010066130 hyper-IgM syndrome Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261612183P | 2012-03-16 | 2012-03-16 | |
| US61/612,183 | 2012-03-16 | ||
| US201261646143P | 2012-05-11 | 2012-05-11 | |
| US61/646,143 | 2012-05-11 | ||
| US201261731428P | 2012-11-29 | 2012-11-29 | |
| US61/731,428 | 2012-11-29 | ||
| PCT/IB2013/001179 WO2013136193A2 (en) | 2012-03-16 | 2013-03-14 | Methods and compositions for modulating toso activity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017162409A Division JP6462800B2 (ja) | 2012-03-16 | 2017-08-25 | Ｔｏｓｏ活性を調節するための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015511599A JP2015511599A (ja) | 2015-04-20 |
| JP2015511599A5 true JP2015511599A5 (enExample) | 2016-04-21 |
| JP6200437B2 JP6200437B2 (ja) | 2017-09-20 |
Family
ID=48747619
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014561543A Expired - Fee Related JP6200437B2 (ja) | 2012-03-16 | 2013-03-14 | Ｔｏｓｏ活性を調節するための方法および組成物 |
| JP2017162409A Expired - Fee Related JP6462800B2 (ja) | 2012-03-16 | 2017-08-25 | Ｔｏｓｏ活性を調節するための方法および組成物 |
| JP2018244907A Expired - Fee Related JP6744391B2 (ja) | 2012-03-16 | 2018-12-27 | Ｔｏｓｏ活性を調節するための方法および組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017162409A Expired - Fee Related JP6462800B2 (ja) | 2012-03-16 | 2017-08-25 | Ｔｏｓｏ活性を調節するための方法および組成物 |
| JP2018244907A Expired - Fee Related JP6744391B2 (ja) | 2012-03-16 | 2018-12-27 | Ｔｏｓｏ活性を調節するための方法および組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US9228006B2 (enExample) |
| EP (2) | EP2825191B1 (enExample) |
| JP (3) | JP6200437B2 (enExample) |
| KR (1) | KR102143887B1 (enExample) |
| CN (1) | CN104394880B (enExample) |
| AU (3) | AU2013234046B2 (enExample) |
| CA (1) | CA2867444C (enExample) |
| IL (1) | IL234683B (enExample) |
| WO (1) | WO2013136193A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102143887B1 (ko) | 2012-03-16 | 2020-08-12 | 유니버시티 헬스 네트워크 | Toso 활성을 조절하기 위한 방법 및 조성물 |
| CA2917077A1 (en) * | 2013-07-03 | 2015-01-08 | University Health Network | Antibodies to toso |
| CA2933200C (en) * | 2014-01-15 | 2025-05-06 | Medimmune Limited | RSV-SPECIFIC ANTIBODIES AND THEIR FUNCTIONAL PARTS |
| JP6538707B2 (ja) * | 2014-03-07 | 2019-07-03 | ユニバーシティ ヘルス ネットワーク | 免疫応答を調節するための方法及び組成物 |
| EP3009841A1 (en) * | 2014-10-14 | 2016-04-20 | Bernhard-Nocht-Institut für Tropenmedizin | Detection of IgM Antibodies using an immune complex (IC) ELISA |
| EP3292143B1 (en) * | 2015-05-04 | 2019-08-21 | Apogenix AG | Single-chain cd40-receptor agonist proteins |
| ES2690420T3 (es) | 2015-05-28 | 2018-11-20 | Universität Zu Köln | Receptor de antígeno quimérico anti-toso y su uso |
| EP3911680A4 (en) | 2019-01-18 | 2022-09-07 | University Health Network | LILRB3 BINDING MOLECULES AND ASSOCIATED USES |
| AU2020222408A1 (en) * | 2019-02-15 | 2021-09-09 | University Health Network | FCMR-binding molecules and uses thereof |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| DE3588239T3 (de) | 1985-03-30 | 2007-03-08 | Kauffman, Stuart A., Santa Fe | Verfahren zum Erhalten von DNS, RNS, Peptiden, Polypeptiden oder Proteinen durch DMS-Rekombinant-Verfahren |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| EP0272253A4 (en) | 1986-03-07 | 1990-02-05 | Massachusetts Inst Technology | METHOD FOR IMPROVING GLYCOPROTE INSTABILITY. |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5763192A (en) | 1986-11-20 | 1998-06-09 | Ixsys, Incorporated | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
| EP0832981A1 (en) | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA sequences to target proteins to the mammary gland for efficient secretion |
| US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| JP2852705B2 (ja) * | 1989-09-15 | 1999-02-03 | タノックス バイオシステムズ インコーポレイテッド | 自己免疫疾患の治療 |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5686073A (en) | 1990-05-23 | 1997-11-11 | The University Of Iowa Research Foundation | Polyclonal and monoclonal antibodies against a 43 KDA dystrophin associated protein |
| WO1992002551A1 (en) | 1990-08-02 | 1992-02-20 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
| US6797492B2 (en) | 1991-05-17 | 2004-09-28 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| ATE228564T1 (de) | 1991-09-13 | 2002-12-15 | Chiron Corp | Zusammensetzung aus mehreren immunreaktiven hepatitis-c-virus-polypeptiden |
| JPH07501694A (ja) * | 1991-11-18 | 1995-02-23 | タノックス バイオシステムズ インコーポレイテッド | 免疫グロブリン生産のアイソタイプ特異的抑制のためのアンチセンスオリゴヌクレオチド |
| JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
| EP1291360A1 (en) | 1991-12-13 | 2003-03-12 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| US5455338A (en) | 1993-11-05 | 1995-10-03 | Zymogenetics, Inc. | DNA encoding novel human kunitz-type inhibitors and methods relating thereto |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| US6709659B1 (en) | 1996-08-02 | 2004-03-23 | Zymogenetics, Inc. | Antibodies that bind testis-specific insulin homolog polypeptides |
| US6727350B2 (en) * | 1997-11-17 | 2004-04-27 | The Board Of Trustees Of The Leland Stanford Junior University | Toso |
| US6555314B1 (en) * | 1998-03-30 | 2003-04-29 | Rigel Pharmaceuticals, Inc. | Toso as a target for drug screening |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| US6683168B1 (en) | 1998-04-21 | 2004-01-27 | Boston Medical Center Corporation | Genes and methods that modulate apoptosis |
| US6322788B1 (en) | 1998-08-20 | 2001-11-27 | Stanley Arthur Kim | Anti-bacterial antibodies and methods of use |
| EP1135498B1 (en) | 1998-11-18 | 2008-01-23 | Genentech, Inc. | Antibody variants with higher binding affinity compared to parent antibodies |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| HK1042648A1 (zh) * | 1999-04-14 | 2002-08-23 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, C/O National Institutes Of Health, Office Of Technology Transfer | 用於诱导对移植物的免疫耐受的含有免疫毒素和抑制树突细胞成熟的试剂的组合物 |
| US6939545B2 (en) | 1999-04-28 | 2005-09-06 | Genetics Institute, Llc | Composition and method for treating inflammatory disorders |
| AU7950400A (en) | 1999-10-19 | 2001-04-30 | Kyowa Hakko Kogyo Co. Ltd. | Process for producing polypeptide |
| AU4721901A (en) * | 2000-02-25 | 2001-09-03 | Immunex Corp | Integrin antagonists |
| ATE549347T1 (de) | 2000-09-08 | 2012-03-15 | Schering Corp | Gene von säugetiere, und damit verbundene reagentien, methoden |
| CN102311986B (zh) | 2000-10-06 | 2015-08-19 | 协和发酵麒麟株式会社 | 产生抗体组合物的细胞 |
| CA2424977C (en) | 2000-10-06 | 2008-03-18 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| EP2322203A3 (en) * | 2002-10-29 | 2011-07-27 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| EP1444989A1 (en) | 2003-02-07 | 2004-08-11 | Giorgio Dr. Stassi | Sensitizing cells for apoptosis by selectively blocking cytokines |
| US7610156B2 (en) | 2003-03-31 | 2009-10-27 | Xencor, Inc. | Methods for rational pegylation of proteins |
| EP2298889A1 (en) | 2004-12-30 | 2011-03-23 | Agency for Science, Technology and Research | Chinese hamster apoptosis-related genes |
| US7119179B1 (en) | 2005-03-21 | 2006-10-10 | Los Alamos National Security, Llc | Preparation of high nitrogen compound and materials therefrom |
| NZ574673A (en) * | 2006-09-08 | 2012-02-24 | Ambrx Inc | Site specific incorporation of non-natural amino acids by vertebrate cells |
| CN101970472B (zh) * | 2007-06-06 | 2013-10-30 | 研究发展基金会 | Rtef-1变体及其用于抑制血管发生的用途 |
| CA2720651C (en) * | 2008-05-01 | 2020-03-10 | Zymogenetics, Inc. | Levels of blys/april heterotrimers in serum and use in diagnostic methods |
| EP2467152B1 (en) | 2009-08-17 | 2017-05-17 | The Penn State Research Foundation | Use of nkg2d inhibitors for treating cardiovascular and metabolic diseases, such as type 2 diabetes |
| KR102143887B1 (ko) | 2012-03-16 | 2020-08-12 | 유니버시티 헬스 네트워크 | Toso 활성을 조절하기 위한 방법 및 조성물 |
| US11392902B2 (en) | 2017-06-06 | 2022-07-19 | United Parcel Service Of America, Inc. | Systems, methods, apparatuses and computer program products for providing notification of items for pickup and delivery |
-
2013
- 2013-03-14 KR KR1020147028977A patent/KR102143887B1/ko not_active Expired - Fee Related
- 2013-03-14 EP EP13734483.4A patent/EP2825191B1/en active Active
- 2013-03-14 CA CA2867444A patent/CA2867444C/en not_active Expired - Fee Related
- 2013-03-14 CN CN201380023772.0A patent/CN104394880B/zh not_active Expired - Fee Related
- 2013-03-14 JP JP2014561543A patent/JP6200437B2/ja not_active Expired - Fee Related
- 2013-03-14 AU AU2013234046A patent/AU2013234046B2/en not_active Ceased
- 2013-03-14 EP EP19186831.4A patent/EP3626254A1/en not_active Withdrawn
- 2013-03-14 WO PCT/IB2013/001179 patent/WO2013136193A2/en not_active Ceased
- 2013-03-14 US US13/831,031 patent/US9228006B2/en not_active Expired - Fee Related
-
2014
- 2014-09-16 IL IL234683A patent/IL234683B/en active IP Right Grant
- 2014-11-12 US US14/539,879 patent/US9670265B2/en not_active Expired - Fee Related
- 2014-11-12 US US14/539,872 patent/US9321824B2/en not_active Expired - Fee Related
- 2014-11-12 US US14/539,884 patent/US9624289B2/en not_active Expired - Fee Related
-
2017
- 2017-05-01 US US15/583,788 patent/US10822388B2/en not_active Expired - Fee Related
- 2017-08-25 JP JP2017162409A patent/JP6462800B2/ja not_active Expired - Fee Related
- 2017-12-05 AU AU2017272172A patent/AU2017272172B2/en not_active Ceased
-
2018
- 2018-12-27 JP JP2018244907A patent/JP6744391B2/ja not_active Expired - Fee Related
-
2019
- 2019-06-28 AU AU2019204594A patent/AU2019204594B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015511599A5 (enExample) | ||
| Hu et al. | The IL‐17 pathway as a major therapeutic target in autoimmune diseases | |
| Crome et al. | Translational mini-review series on Th17 cells: function and regulation of human T helper 17 cells in health and disease | |
| TWI713798B (zh) | 增加介白素－２（ｉｌ－２）分泌量之方法和源自該方法之蛋白類 | |
| JP2018528237A5 (enExample) | ||
| JP2019519215A5 (enExample) | ||
| JP2017018125A5 (enExample) | ||
| JP2016527891A5 (enExample) | ||
| IL278014B2 (en) | Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use | |
| CN107001438A (zh) | 白细胞介素‑15组合物及其用途 | |
| JP2015524413A5 (enExample) | ||
| HRP20200230T1 (hr) | Polipeptidi antitijela koji antagoniziraju cd40l | |
| JP2014523238A5 (enExample) | ||
| BRPI0806578A8 (pt) | Promotores de lactococcus e usos dos mesmos | |
| JP2017538401A5 (enExample) | ||
| RU2022103870A (ru) | Модифицированный иммунорегуляторный элемент и изменение иммунитета посредством этого элемента | |
| TW201129379A (en) | Anti-Orai1 antigen binding proteins and uses thereof | |
| NZ739448A (en) | Transgene genetic tags and methods of use | |
| ME03796B (me) | Anti-lag-3 vezujući proteini | |
| AR086360A1 (es) | Polipeptidos anticuerpos que antagonizan cd40 | |
| IL269187B1 (en) | Dominant active yap, a hippo effector, induces chromatin accessiblity and cardiomyocyte renewal | |
| AU2017224111A1 (en) | Transposon system and methods of use | |
| FI2956471T3 (fi) | Il-1-beetan estäjän koostumus ja sen käyttö | |
| RU2017127024A (ru) | Герпесвирус с измененным спектром мишеней, содержащий гибридный гликопротеин н | |
| JP2017502691A (ja) | ヒトｆｇｆｒ２ｂ細胞外ドメイン及びそれをコードする核酸 |